BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

475 related articles for article (PubMed ID: 25465343)

  • 41. Impact on survival of time from definitive surgery to initiation of adjuvant chemotherapy for early-stage breast cancer.
    Lohrisch C; Paltiel C; Gelmon K; Speers C; Taylor S; Barnett J; Olivotto IA
    J Clin Oncol; 2006 Oct; 24(30):4888-94. PubMed ID: 17015884
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Safety and Efficacy of Oxaliplatin Doublet Adjuvant Chemotherapy in Elderly Patients With Stage III Colon Cancer.
    Brungs D; Aghmesheh M; de Souza P; Carolan M; Clingan P; Rose J; Ranson M
    Clin Colorectal Cancer; 2018 Sep; 17(3):e549-e555. PubMed ID: 29861156
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical impact of elastic laminal invasion in colon cancer: elastic laminal invasion-positive stage II colon cancer is a high-risk equivalent to stage III.
    Yokota M; Kojima M; Nomura S; Nishizawa Y; Kobayashi A; Ito M; Ochiai A; Saito N
    Dis Colon Rectum; 2014 Jul; 57(7):830-8. PubMed ID: 24901683
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Impact of timing of adjuvant chemotherapy on survival in stage III colon cancer: a population-based study.
    Gao P; Huang XZ; Song YX; Sun JX; Chen XW; Sun Y; Jiang YM; Wang ZN
    BMC Cancer; 2018 Mar; 18(1):234. PubMed ID: 29490625
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Oncologic outcomes after adjuvant chemotherapy with capecitabine compared to 5-fluorouracil/leucovorin for geriatric stage II colon cancer: a retrospective cohort study.
    Lee KY; Park JW; Lee KY; Cho S; Kwon YH; Kim MJ; Ryoo SB; Jeong SY; Park KJ
    Int J Colorectal Dis; 2019 Apr; 34(4):629-639. PubMed ID: 30661101
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A Japanese multicenter phase II study of adjuvant chemotherapy with mFOLFOX6/CAPOX for stage III colon cancer treatment after D2/D3 lymphadenectomy.
    Yoshimatsu K; Ishibashi K; Koda K; Yokomizo H; Oda N; Oshiro M; Kato H; Oya M; Nakajima H; Ooki S; Maekawa H; Matsunami T; Tsubaki M; Yamada T; Kobayashi M; Tanakaya K; Yokoyama M; Ishida H
    Surg Today; 2019 Jun; 49(6):498-506. PubMed ID: 30953164
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Impact of Patient Factors on Recurrence Risk and Time Dependency of Oxaliplatin Benefit in Patients With Colon Cancer: Analysis From Modern-Era Adjuvant Studies in the Adjuvant Colon Cancer End Points (ACCENT) Database.
    Shah MA; Renfro LA; Allegra CJ; André T; de Gramont A; Schmoll HJ; Haller DG; Alberts SR; Yothers G; Sargent DJ
    J Clin Oncol; 2016 Mar; 34(8):843-53. PubMed ID: 26811529
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Benefit of adjuvant chemotherapy in patients with T4 UICC II colon cancer.
    Teufel A; Gerken M; Hartl J; Itzel T; Fichtner-Feigl S; Stroszczynski C; Schlitt HJ; Hofstädter F; Klinkhammer-Schalke M
    BMC Cancer; 2015 May; 15():419. PubMed ID: 25985893
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Associations and prognostic implications of Eastern Cooperative Oncology Group performance status and tumoral LINE-1 methylation status in stage III colon cancer patients.
    Chen D; Wen X; Song YS; Rhee YY; Lee TH; Cho NY; Han SW; Kim TY; Kang GH
    Clin Epigenetics; 2016; 8():36. PubMed ID: 27051466
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Irinotecan and Oxaliplatin Might Provide Equal Benefit as Adjuvant Chemotherapy for Patients with Resectable Synchronous Colon Cancer and Liver-confined Metastases: A Nationwide Database Study.
    Liang YH; Shao YY; Chen HM; Cheng AL; Lai MS; Yeh KH
    Anticancer Res; 2017 Dec; 37(12):7095-7104. PubMed ID: 29187501
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of age on survival benefit of adjuvant chemotherapy in elderly patients with Stage III colon cancer.
    Zuckerman IH; Rapp T; Onukwugha E; Davidoff A; Choti MA; Gardner J; Seal B; Mullins CD
    J Am Geriatr Soc; 2009 Aug; 57(8):1403-10. PubMed ID: 19563521
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Is oxaliplatin combined with weekly bolus 5-fluorouracil and leucovorin an option for stage II and III colon cancer?
    Twelves C
    Nat Clin Pract Oncol; 2008 Feb; 5(2):72-3. PubMed ID: 18030299
    [No Abstract]   [Full Text] [Related]  

  • 53. The efficacy of oral tegafur-uracil as maintenance therapy following intravenous 5-fluorouracil chemotherapy in stage III colon cancer.
    Hong KD; Lee SI; Moon HY
    Hepatogastroenterology; 2012; 59(113):104-7. PubMed ID: 22251527
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Randomized trial of adjuvant therapy in colon carcinoma: 10-year results of NSABP protocol C-01.
    Smith RE; Colangelo L; Wieand HS; Begovic M; Wolmark N
    J Natl Cancer Inst; 2004 Aug; 96(15):1128-32. PubMed ID: 15292384
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The toxicity and efficacy of Nordic-FLOX regimen as adjuvant treatment of stage III colon cancer.
    Demir L; Somali I; Oktay Tarhan M; Erten C; Ellidokuz H; Can A; Dirican A; Vedat Bayoglu I
    J BUON; 2011; 16(4):682-8. PubMed ID: 22331722
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Reasons for Underuse of Adjuvant Chemotherapy in Elderly Patients With Stage III Colon Cancer.
    Ko JJ; Kennecke HF; Lim HJ; Renouf DJ; Gill S; Woods R; Speers C; Cheung WY
    Clin Colorectal Cancer; 2016 Jun; 15(2):179-85. PubMed ID: 26520019
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Nuclear orphan receptor NR4A2 confers chemoresistance and predicts unfavorable prognosis of colorectal carcinoma patients who received postoperative chemotherapy.
    Han Y; Cai H; Ma L; Ding Y; Tan X; Liu Y; Su T; Yu Y; Chang W; Zhang H; Fu C; Cao G
    Eur J Cancer; 2013 Nov; 49(16):3420-30. PubMed ID: 23809767
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Adjuvant chemotherapy increase survival and decrease recurrence in stage IIA colon cancer.
    Yun HR; Kim HC; Yun SH; Lee WY
    Hepatogastroenterology; 2012; 59(120):2466-71. PubMed ID: 23169179
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The updated five-year overall survival and long-term oxaliplatin-related neurotoxicity assessment of the FACOS study.
    Takeshita E; Ishibashi K; Koda K; Oda N; Yoshimatsu K; Sato Y; Oya M; Yamaguchi S; Nakajima H; Momma T; Maekawa H; Tsubaki M; Yamada T; Kobayashi M; Tanakaya K; Ishida H
    Surg Today; 2021 Aug; 51(8):1309-1319. PubMed ID: 33586034
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Impact of adjuvant chemotherapy cycles on prognosis of resectable stomach cancer: a retrospective analysis.
    Zhang WY; Zhang WJ; Bai Y; Yuan HH; Liu F; Gao J; Gong YF; Jiang B
    Asian Pac J Cancer Prev; 2013; 14(1):381-6. PubMed ID: 23534757
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.